Enhancing study success with advanced clinical research technologies and expert solutions for Psoriatic Arthritis trials.
Psoriatic Arthritis
Trial Solutions
Effective solutions for advancing Psoriatic Arthritis research
Although therapeutic options have advanced significantly in recent years, clinical trials play an important role in testing new therapies and establishing optimal treatment strategies for psoriatic arthritis (PsA). Signant Health can apply decades of direct clinical experience, deep therapeutic-area expertise, and innovative clinical trial technologies within our Signant SmartSignals platform to help researchers test and achieve approval for new therapies and treatment options.
Why Signant Health
- Collect Complete, Accurate Endpoint Data
- Optimize Endpoint Reliability
- Launch PsA Studies Faster
- Gain Additional Patient Function Insights
- Simplify Long Term Follow Up Visits
-
Collect Complete, Accurate Endpoint Data
Collect Complete, Accurate Endpoint Data
Protocols for PsA research typically include a combination of ClinRO and PRO assessments. Whether they are administered at site or at home, ensure endpoint data they generate are accurate and reliable by leveraging our flexible, customizable eCOA platform. We'll support your team with clinical and eCOA specialists who understand the nuances of psoriatic arthritis research. -
Optimize Endpoint Reliability
Optimize Endpoint Reliability
Ensure accurate, reliable primary endpoint data. Developed by clinicians for clinicians, our Rater Training solution improves accuracy and consistency in assessment administration and scoring.
Another key component of successful PsA studies, Blinded Data Analytics corrects quality issues through the course of a study. We examine study data at all relevant levels to identify quality concerns that impact endpoint reliability, and then recommend intervention methods to correct and prevent reoccurrence of the issue. -
Launch PsA Studies Faster
Launch PsA Studies Faster
Accelerate the study startup process by obtaining informed consent, enrolling, and randomizing patients faster using our Signant SmartSignals RTSM and eConsent solutions. Both include options that allow for rapid deployment and simplified protocol amendment implementation. Plus, these solutions facilitate decentralized study designs. -
Gain Additional Patient Function Insights
Gain Additional Patient Function Insights
Sleep quality and activity measures provide relevant, objective insights into PsA patient function and quality of life. Layer ActiGraph into your eCOA strategy to automatically collect sleep and activity data, with no additional burden on patients or sites.Data can be viewed together with COA data for a more complete assessment of treatment impact or patient function.
-
Simplify Long Term Follow Up Visits
Simplify Long Term Follow Up Visits
Make it more convenient to participate in your PsA study so patients remain enrolled and compliant with protocol requirements. Video-based telemedicine consultations reduce burdens for participants and offer sites an efficient means of monitoring safety and conducting assessments that are suitable for remote conduct.
Comprehensive Psoriatic Arthritis experience
0
STUDIES
0
PATIENTS
0
COUNTRIES
0
SITES
Explore our Psoriatic Arthritis trial resources
CASE STUDY
READ CASE STUDY
Signant’s Scale Management Expertise Facilitates Endpoint Accuracy & Reliability in Psoriatic Arthritis Trial
eClinical solutions for Psoriatic Arthritis trials
Ready to learn more?
Discover how Signant can support your current or upcoming psoriatic arthritis trials.